New Data Could Boost 'Switching' To Biosimilar Infliximab
This article was originally published in Scrip
Executive Summary
New data that could help boost biosimilar infliximab uptake has been presented from "the largest real-world study to date" showing the effectiveness of the biosimilar infliximab Remsima in patients with inflammatory bowel diseases who have been switched from the reference product infliximab.